



2025 Prescrire Information Awards

Prescrire’s annual Information Awards are based on pharmaceutical companies’ responses to requests by Prescrire’s Editorial Staff for the information we need to produce the analyses published in the Marketing Authorisations section of our French edition. Prescrire’s Information Awards reflect the level of transparency that companies have shown towards Prescrire over the year.

What information does Prescrire request from pharmaceutical companies, and why?

Pharmaceutical companies hold a wealth of data that are not available elsewhere. Since its inception, Prescrire has therefore systematically asked companies to send us data on their products, from the drug development stage through to post-marketing surveillance. We also conduct a systematic search for information from other sources, such as health authorities and the scientific literature.

We mainly ask for: evaluation data concerning the drug’s efficacy and adverse effects; its packaging; the conditions under which patients can access the drug; its reimbursement status in France; its availability; and, where applicable, the reasons for its market withdrawal. Prescrire’s Editorial Staff analyse all the information and materials companies provide.

The purpose of these requests is to help keep healthcare professionals fully informed and up to date, in order to improve the quality of patient care, by promoting the correct use of drugs and by increasing patient safety.

Only 9 pharmaceutical companies made the 2025 Honours List.

9 of the 85 pharmaceutical companies from which Prescrire requested information in 2025 earned a place on this year’s Information Awards Honours List, for providing useful documentation that addressed every aspect of our requests. One of them, Cevibra, was rated as “Outstanding” for its rapid response times and the provision of detailed documentation, including particularly useful information and documents that are not publicly available, such as:

- Clinical study reports, providing details about the results of clinical trials;
- A periodic benefit-risk evaluation report (PBRER), enabling a better understanding of the drug’s risks, through the data collected since its market introduction;
- Other documents containing information about clinical trials, such as their protocols and statistical analysis plans;
- Photos of packaging items.

Conversely, 15 pharmaceutical companies decided not to provide Prescrire with any information or documentation. These companies received an information “Red Card” (see figure opposite).

Unpublished data that are useful for healthcare professionals: what does Prescrire expect from companies?

One of the pharmaceutical companies on this year’s Honours List, Cemag Care, sent us detailed and appropriate documentation about its product, but omitted to mention that it had also applied to the French Health Products Agency (ANSM) to reclassify the substance concerned, in order to be able to market the product over the counter. This information would have been useful for Prescrire’s analysis.

When Prescrire requests information from a pharmaceutical company, we expect to receive all important data relating to the product, so that we can analyse them and provide health professionals with any information relevant to health care.

More transparency. Other pharmaceutical companies that we contact frequently, such as GlaxoSmithKline, Lilly, Roche, Takeda and Viatrix, earned a place on this year’s Honours List for their regular and rapid responses to our requests. Their responses were partial, however. More comprehensive responses, including all the relevant data of use to healthcare professionals and patients, would be a sign of greater transparency. Prescrire encourages them to go that extra mile!

Transparency towards teams such as Prescrire, whose aim is to promote high-quality health care, first and foremost in the interest of patients, should be an ethical requirement for pharmaceutical companies.


©Prescrire

► Translated from *Rev Prescrire* February 2026
Volume 46 N° 508 • Page 89



Prescrire Information Awards

Of the 85 companies we contacted for information



9 companies made the Honours List



61 companies neither made the Honours List nor received a Red Card



15 companies received a Red Card

Honours List



Outstanding:
Cevibra



Followed by:
Celltrion Healthcare, Cemag Care, EG Labo, GlaxoSmithKline, Lilly, Roche, Takeda, Viatrix

Red Cards



Alexion, Ammirall, Bayer Healthcare, Gedeon Richter, Intsel Chimos, Janssen-Cilag, Kyowa Kirin Pharma, Orion Pharma, Otsuka Pharmaceutical, Panpharma, PharmaBlue, Teva, Theramex, UCB Pharma, Zentiva